Back to School: How biopharma can reboot drug development. Access exclusive analysis here

1009 ECP A2
BioCentury & Getty Images

Emerging Company Profile

A2: targeting lost genetic material to distinguish tumors from normal cells

A2 will use its $71.5M series B to advance up to three clinical solid tumor programs

A2 uses its dual engineered T cell platform to kill tumor cells while protecting healthy cells by targeting the loss of genetic material.

Oct 9, 2020 | 10:14 PM GMT

A2

Read the full 630 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE